DAFNA Capital Management
Latest statistics and disclosures from DAFNA Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RVMD, XBI, STXS, DAWN, ATRC, and represent 36.48% of DAFNA Capital Management's stock portfolio.
- Added to shares of these 10 stocks: CMPS (+$8.9M), NKTR (+$6.5M), LRMR, BCAX, FULC, KIDS, CTMX, MAZE, SCYX, RARE.
- Started 10 new stock positions in SCYX, IBIO, CTMX, NMRA, MAZE, NAMS, ZBIO, FULC, KIDS, PLRX.
- Reduced shares in these 10 stocks: CYTK (-$10M), AXGN (-$7.5M), Astria Therapeutics, RVMD, XBI, XENE, KALV, EWTX, SNDX, ASND.
- Sold out of its positions in Astria Therapeutics, BWAY, ERAS, CATX.
- DAFNA Capital Management was a net seller of stock by $-4.2M.
- DAFNA Capital Management has $440M in assets under management (AUM), dropping by 2.11%.
- Central Index Key (CIK): 0001389933
Tip: Access up to 7 years of quarterly data
Positions held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for DAFNA Capital Management
DAFNA Capital Management holds 83 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Revolution Medicines (RVMD) | 12.8 | $57M | -3% | 581k | 97.25 |
|
| Spdr S&p Biotech Etf Etf (XBI) | 9.3 | $41M | -5% | 319k | 127.73 |
|
| Stereotaxis Com New (STXS) | 5.7 | $25M | 14M | 1.84 |
|
|
| Day One Biopharmaceuticals I (DAWN) | 4.8 | $21M | -2% | 979k | 21.44 |
|
| AtriCure (ATRC) | 3.9 | $17M | 597k | 28.53 |
|
|
| Ideaya Biosciences (IDYA) | 3.6 | $16M | -5% | 477k | 33.32 |
|
| Xenon Pharmaceuticals (XENE) | 3.3 | $15M | -12% | 251k | 58.15 |
|
| Cytokinetics Com New (CYTK) | 3.3 | $14M | -41% | 218k | 65.91 |
|
| Compass Pathways Sponsored Ads (CMPS) | 3.0 | $13M | +198% | 2.4M | 5.53 |
|
| Nektar Therapeutics Com New (NKTR) | 2.7 | $12M | +120% | 165k | 71.95 |
|
| Ishares Nasdaq Biotech Indx Etf (IBB) | 2.4 | $11M | -8% | 62k | 168.85 |
|
| Arcus Biosciences Incorporated (RCUS) | 2.2 | $9.6M | +2% | 444k | 21.60 |
|
| Neurocrine Biosciences (NBIX) | 2.1 | $9.3M | 71k | 131.74 |
|
|
| Larimar Therapeutics (LRMR) | 2.1 | $9.1M | +116% | 2.0M | 4.50 |
|
| Bicara Therapeutics (BCAX) | 1.9 | $8.4M | +61% | 422k | 19.89 |
|
| Axogen (AXGN) | 1.9 | $8.3M | -47% | 250k | 33.13 |
|
| Biohaven (BHVN) | 1.6 | $7.2M | -11% | 846k | 8.46 |
|
| Tandem Diabetes Care Com New (TNDM) | 1.5 | $6.8M | 355k | 19.17 |
|
|
| Denali Therapeutics (DNLI) | 1.4 | $6.1M | 319k | 19.20 |
|
|
| Ascendis Pharma A/s Note 2.250% 4/0 (Principal) | 1.3 | $5.9M | 4.0M | 1.48 |
|
|
| Century Therapeutics (IPSC) | 1.3 | $5.5M | -12% | 2.4M | 2.26 |
|
| Dex (DXCM) | 1.2 | $5.4M | -2% | 86k | 62.80 |
|
| Kalvista Pharmaceuticals (KALV) | 1.2 | $5.4M | -25% | 267k | 20.13 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 1.2 | $5.3M | -17% | 23k | 228.73 |
|
| Mbx Biosciences (MBX) | 1.2 | $5.2M | +6% | 176k | 29.85 |
|
| Inogen (INGN) | 1.2 | $5.2M | +2% | 845k | 6.18 |
|
| Syndax Pharmaceuticals (SNDX) | 1.2 | $5.1M | -21% | 217k | 23.36 |
|
| Alkermes SHS (ALKS) | 1.1 | $4.9M | +7% | 140k | 35.36 |
|
| Stoke Therapeutics (STOK) | 1.0 | $4.3M | +20% | 131k | 32.56 |
|
| BioCryst Pharmaceuticals (BCRX) | 0.9 | $4.1M | +2% | 430k | 9.52 |
|
| Galapagos Nv Spon Adr (GLPG) | 0.9 | $3.9M | 130k | 30.00 |
|
|
| Immunovant (IMVT) | 0.9 | $3.7M | 151k | 24.84 |
|
|
| Edgewise Therapeutics (EWTX) | 0.8 | $3.5M | -29% | 112k | 31.50 |
|
| Maplight Therapeutics (MPLT) | 0.8 | $3.5M | +18% | 171k | 20.33 |
|
| Allogene Therapeutics (ALLO) | 0.8 | $3.3M | 1.4M | 2.44 |
|
|
| Procept Biorobotics Corp (PRCT) | 0.7 | $3.0M | 120k | 25.01 |
|
|
| Align Technology (ALGN) | 0.6 | $2.6M | -6% | 15k | 171.43 |
|
| Proqr Therapeutics N V Shs Euro (PRQR) | 0.6 | $2.5M | 1.6M | 1.62 |
|
|
| Cybin Com New (HELP) | 0.5 | $2.4M | +9% | 498k | 4.80 |
|
| Rapport Therapeutics (RAPP) | 0.5 | $2.3M | 75k | 31.29 |
|
|
| Insulet Corporation (PODD) | 0.5 | $2.3M | +58% | 11k | 209.84 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.5 | $2.2M | +25% | 47k | 48.20 |
|
| Immatics Nv SHS (IMTX) | 0.5 | $2.2M | -13% | 226k | 9.84 |
|
| Celldex Therapeutics Com New (CLDX) | 0.5 | $2.2M | 69k | 31.72 |
|
|
| Lexeo Therapeutics (LXEO) | 0.5 | $2.2M | +10% | 377k | 5.74 |
|
| Alector (ALEC) | 0.4 | $2.0M | 908k | 2.15 |
|
|
| Viking Therapeutics (VKTX) | 0.4 | $1.9M | 60k | 32.54 |
|
|
| Kura Oncology (KURA) | 0.4 | $1.9M | 236k | 8.13 |
|
|
| Profound Medical Corp Com New (PROF) | 0.4 | $1.7M | -7% | 263k | 6.48 |
|
| Fulcrum Therapeutics (FULC) | 0.4 | $1.6M | NEW | 205k | 7.67 |
|
| Aquestive Therapeutics (AQST) | 0.3 | $1.5M | 368k | 4.15 |
|
|
| Mediwound Shs New (MDWD) | 0.3 | $1.5M | -16% | 94k | 16.11 |
|
| Orthopediatrics Corp. (KIDS) | 0.3 | $1.5M | NEW | 96k | 15.87 |
|
| Ultragenyx Pharmaceutical (RARE) | 0.3 | $1.3M | +281% | 61k | 20.95 |
|
| Engene Holdings (ENGN) | 0.3 | $1.3M | +14% | 187k | 6.81 |
|
| Neurogene (NGNE) | 0.3 | $1.1M | +102% | 57k | 20.16 |
|
| Silverback Therapeutics (SPRY) | 0.3 | $1.1M | -26% | 139k | 8.03 |
|
| Cytomx Therapeutics (CTMX) | 0.2 | $1.1M | NEW | 230k | 4.70 |
|
| Maze Therapeatics (MAZE) | 0.2 | $1.0M | NEW | 35k | 29.85 |
|
| Mineralys Therapeutics (MLYS) | 0.2 | $1.0M | 39k | 27.09 |
|
|
| Scynexis Com New (SCYX) | 0.2 | $997k | NEW | 1.1M | 0.92 |
|
| Oric Pharmaceuticals (ORIC) | 0.2 | $946k | -30% | 99k | 9.58 |
|
| Inspire Med Sys (INSP) | 0.2 | $939k | +111% | 18k | 51.58 |
|
| Polypid (PYPD) | 0.2 | $911k | 208k | 4.38 |
|
|
| Tela Bio (TELA) | 0.2 | $893k | 1.4M | 0.62 |
|
|
| Zenas Biopharma (ZBIO) | 0.2 | $831k | NEW | 43k | 19.55 |
|
| Verrica Pharmaceuticals Com Shs (VRCA) | 0.2 | $813k | -11% | 154k | 5.29 |
|
| Fate Therapeutics (FATE) | 0.2 | $660k | 550k | 1.20 |
|
|
| Annexon (ANNX) | 0.1 | $653k | -56% | 118k | 5.54 |
|
| Accuray Incorporated (ARAY) | 0.1 | $652k | +20% | 1.7M | 0.39 |
|
| Newamsterdam Pharma Ordinary Shares (NAMS) | 0.1 | $640k | NEW | 20k | 32.01 |
|
| Adicet Bio Com New (ACET) | 0.1 | $639k | 94k | 6.81 |
|
|
| Biontech Se Sponsored Ads (BNTX) | 0.1 | $622k | 7.0k | 88.88 |
|
|
| Pliant Therapeutics (PLRX) | 0.1 | $614k | NEW | 487k | 1.26 |
|
| Compugen Ord (CGEN) | 0.1 | $549k | -5% | 258k | 2.13 |
|
| Health Sciences Acq Corp 2 (OBIO) | 0.1 | $539k | 127k | 4.25 |
|
|
| Foghorn Therapeutics (FHTX) | 0.1 | $535k | -11% | 112k | 4.78 |
|
| Ibio Com New (IBIO) | 0.1 | $368k | NEW | 194k | 1.90 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.1 | $299k | 65k | 4.64 |
|
|
| Adc Therapeutics Sa SHS (ADCT) | 0.1 | $270k | -6% | 72k | 3.75 |
|
| Karyopharm Therapeutics Com New (KPTI) | 0.1 | $255k | -10% | 46k | 5.57 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.1 | $248k | 179k | 1.38 |
|
|
| Neumora Therapeutics (NMRA) | 0.0 | $137k | NEW | 70k | 1.95 |
|
Past Filings by DAFNA Capital Management
SEC 13F filings are viewable for DAFNA Capital Management going back to 2010
- DAFNA Capital Management 2026 Q1 filed May 15, 2026
- DAFNA Capital Management 2025 Q4 filed Feb. 17, 2026
- DAFNA Capital Management 2025 Q3 filed Nov. 14, 2025
- DAFNA Capital Management 2025 Q2 filed Aug. 14, 2025
- DAFNA Capital Management 2025 Q1 filed May 15, 2025
- DAFNA Capital Management 2024 Q4 filed Feb. 14, 2025
- DAFNA Capital Management 2024 Q3 filed Nov. 14, 2024
- DAFNA Capital Management 2024 Q2 filed Aug. 14, 2024
- DAFNA Capital Management 2024 Q1 filed May 15, 2024
- DAFNA Capital Management 2023 Q4 filed Feb. 14, 2024
- DAFNA Capital Management 2023 Q3 filed Nov. 14, 2023
- DAFNA Capital Management 2023 Q2 filed Aug. 14, 2023
- DAFNA Capital Management 2023 Q1 filed May 15, 2023
- DAFNA Capital Management 2022 Q4 filed Feb. 14, 2023
- DAFNA Capital Management 2022 Q3 filed Nov. 14, 2022
- DAFNA Capital Management 2022 Q2 filed Aug. 15, 2022